Drug Combination Details
| General Information of the Combination (ID: C04523) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [1] | ||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | |||
|
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [2] | |||
|
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [3] | |||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [4] | |||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [5] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | ||||||
| Molecule(s)
Regulation |
. | . | Molecule Info | |||
| In-vitro Model | 5637 | CVCL_0126 | Bladder carcinoma | Homo sapiens | ||
| T24 | CVCL_0554 | Bladder carcinoma | Homo sapiens | |||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Resveratrol potentiates cytotoxic properties of doxorubicin used in the study through increasing their intracellular level due to p-glycoprotein inhibition and downregulation of mdr1 gene. | |||||
| Experiment 3 Reporting the Effect of This Combination | [6] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GABPA | Molecule Info | |||
| Down-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Animals were maintained at standard condition and exponentially grown 1*106 EAC cells collected from peritoneal cavity from Ascitic mice, and were inoculated into the peritoneal cavity of fresh healthy male Swiss Albino mice. | |||||
| Experimental
Result(s) |
Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy. | |||||
| Experiment 4 Reporting the Effect of This Combination | [4] | |||||
| In-vitro Model | PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The cells' viability was more affected when DOX:RES combinations containing higher contents of RES (1:2-1:5 molar ratios) were used. This can be explained by the ability of RES to reduce the P-glycoprotein (P-gp)-mediated efflux of DOX. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [7] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MSH3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | MCF-7/adr cells (5*105 cells in 0.1mL) suspended in serum-free medium containing 50% Matrigel were inoculated subcutaneously through 25-gauge needles into the right flank of each nude mouse. | |||||
| Experimental
Result(s) |
Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | S6K1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TSC1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TSC2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | ||
| MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
| In-vivo Model | 1*107 SGC7901/DOX cells were injected subcutaneously into the left inguinal region of each nude mouse when the mice got five weeks old. | |||||
| Experimental
Result(s) |
RES serves as a novel solution to reverse the DOX-resistance of gastric cancer via preventing EMT by modulating PTEN/Akt signaling pathway. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Down-regulation | P-gp efflux | ||||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity. | |||||
| Experiment 4 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SIRT1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| MCF-10A | CVCL_0598 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/beta-catenin signaling pathway in breast cancer. | |||||
